Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04589845 · ClinicalTrials.gov registry record · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
A Phase 2 study of Solid Tumors, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 920
- Enrollment target
- 20
- Study locations
NCT04589845 is a Phase 2 study of Solid Tumors that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 920 participants, above the 277-participant average among 125 other Solid Tumors trials with a reported enrollment target (232% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT04589845, a Phase 2 study of Solid Tumors, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 920 participants
- Enrollment target
- 20
- Study locations
Study Summary
TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assay. Participants with solid tumors will be treated with a drug or drug regimen tailored to their NGS assay results at screening. Participants will be assigned to the appropriate cohort based on their genetic alteration(s). Treatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.
Conditions Studied
Interventions
- DRUG Atezolizumab
- DRUG Ipatasertib
- DRUG Alectinib
- DRUG Entrectinib
Study Locations (20)
California
- City of Hope National Medical Center - Duarte
- Kaiser Permanente Los Angeles - Los Angeles
- USC Norris Cancer Center - Los Angeles
- Hoag Memorial Hospital - Newport Beach
- UC Davis Comprehensive Cancer Center - Sacramento
- University of California at San Francisco - San Francisco
- Sarcoma Oncology Center - Santa Monica
Florida
- University of Florida - Gainesville
- Miami Cancer Institute of Baptist Health, Inc. - Miami
- Ocala Oncology Center - Ocala
Alabama
- Southern Cancer Center - Daphne
Arizona
- Western Regional Medical Center at Cancer Treatment Centers of America - Goodyear
Colorado
- Children's Hospital Colorado - Aurora
Delaware
- Christiana Care Health Srvcs - Newark
Georgia
- University Cancer & Blood Center, LLC - Athens
Idaho
- St. Alphonsus - Boise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 920 participants |
| Start Date | 2021-01-18 |
| Est. Completion | 2032-09-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04589845
The ClinicalTrials.gov registry entry for NCT04589845 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 920 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 277-participant average among 125 other Solid Tumors trials with a reported enrollment target (232% higher). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Atezolizumab is the first listed.
NCT04589845 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT04589845 about?
NCT04589845 is a clinical study titled "Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study". TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or in rational, specified combinations in participants with unresectable, locally advanced or metastatic solid tumors deter...
What is the current status of trial NCT04589845?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 920 participants. The study started on 2021-01-18. Estimated completion is 2032-09-25.
What conditions does trial NCT04589845 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT04589845?
The interventions under investigation include: Atezolizumab (DRUG), Ipatasertib (DRUG), Alectinib (DRUG), Entrectinib (DRUG).
Who is sponsoring clinical trial NCT04589845?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04589845 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
RECRUITING · Phase 2
-
Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors
RECRUITING · Phase 2
-
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
-
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.